Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Fischer, K
Br J Community Nurs 2011;16(5):222
You simply swallow a pill, and you dont have to worry about poking yourself with a needle
If there's a pill version, if there's an alternate version, I think that's going to free up the injectable version more
Safety Profiles Side by Side Gastrointestinal Adverse Events | Event | Tirzepatide 15 mg (SURMOUNT-1) | Retatrutide 12 mg (Phase 2) | |---|---|---| | Nausea | 31% | 47% | | Vomiting | 16% | 25% | | Diarrhea | 22% | 17% | | Constipation | 19% | 13% | | Discontinuation due to GI AEs | 4.3% | 16.6% | Discontinuation rates in the retatrutide phase 2 trial were substantially higher than those seen in tirzepatide's phase 3 program, which may reflect a steeper titration schedule, the additional glucagon receptor burden, or the smaller trial population amplifying extreme responders [2][3]
US$ 28.07
US$ 23.55
US$ 22.31
US$ 29.11
US$ 27.73
US$ 28.71
US$ 26.48
US$ 24.80
